e-journal

Prospective, Non-interventional Study on the Real-World Use of Certoparin in Daily Practice—The PROMEMBER Study

---

We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding. Methods: This was a non-interventional study documenting patients at hospital- or office-based physicians. Results: Patients’ (n ¼ 1407) mean age was 53.7+16.1 years. Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%) patients and treatment in 76 (5.4%) patients. In only 11.4% of those receiving prophylaxis and 13.2% of those receiving treatment dosing, duration and schedule of certoparinwerewithin label. There were 2 patientswith deep venous thrombosis ([DVT], no pulmonary embolism [PE]), and 51 patients (3.8%) with minor (nonmajor) bleeding complications in patients receiving prophylaxis. Two patients treated with certoparin had recurrent DVT and one had PE (one patient with minor bleeding). Conclusions: Certoparin is very effective in real
world. This also applies to patients in whom clinical decision making leads to an alteration of recommended application.

Keywords anticoagulation, certoparin, thromboembolism, bleeding, real world

---

Ketersediaan

Tidak ada salinan data

Informasi Detail

Judul Seri

Clinical and Applied Thrombosis/Hemostasis

No. Panggil

-

Penerbit

: SAGE Publications Ltd., 2013

Deskripsi Fisik

Clinical and Applied Thrombosis/Hemostasis 19(1) 86-91 ª The Author(s) 2013

Bahasa

English

ISBN/ISSN

-

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

FARMASI

Info Detail Spesifik

-

Pernyataan Tanggungjawab

hasnidar/agus

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar